Primordial Origins of RNA Therapeutics

In-person only.

Dr. Ehlers grew up in rural Nebraska and earned his bachelor’s degree in chemistry from Caltech. He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. At ATP, Dr. Ehlers directs the fund’s science-driven investment strategy by identifying and evaluating new breakthrough science around the world and turning it into business plans, management teams, and drug discovery and development programs. Dr. Ehlers is co-founder and CEO Ascidian Therapeutics, an RNA editing company developing exon editing technology for gene correction in hereditary diseases; co-founder and Chair of Aulos Bioscience, an immunooncology company advancing computationally-designed antibody therapeutics targeting interleukin-2 for diverse cancers; and co-founder and Chair of Replicate Bioscience, an RNA therapeutics company developing self-replicating RNA technologies for the treatment of infectious disease and cancer. Prior to joining ATP and its portfolio companies in 2019, Dr. Ehlers was Executive Vice President for Research & Development at Biogen, one of the world’s oldest and largest biopharmaceutical companies. At Biogen, Dr. Ehlers directed global research and development including discovery sciences, translational
medicine, clinical development, and regulatory sciences with a focus on neurological, immunological, and rare diseases. During his time at Biogen, he advanced 20 novel clinical candidate compounds including overseeing the approval of SPINRAZAä(nusinersen), the first drug approved for spinal muscular atrophy, and VUMERITYä (diroximel fumarate), the second oral fumarate approved for multiple sclerosis, as well as advancing development programs for currently approved LEQEMBIä, the first fully approved drug for slowing cognitive decline in Alzheimer’s disease, and QALSODYä, the first genetic medicine for ALS. Before Biogen, Dr. Ehlers was Senior Vice President for BioTherapeutics and Chief Scientific Officer for Neuroscience at Pfizer where he created and advanced the Neuroscience and Rare Disease portfolios at Pfizer, successfully bringing 22 compounds into the clinic as well as directing global development activities in biologics design, synthesis, and manufacturing, and steering a network of academic collaborations focused on immunology and oncology. Before entering his industry career in 2010, he was George Barth Geller Professor and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center, where he pioneered studies on neuronal organelles and the trafficking of neurotransmitter receptors. Dr. Ehlers is the recipient of numerous awards including the 2003 Eppendorf & Science Prize in Neurobiology, the 2007 John J. Abel Award in Pharmacology, the 2007 Society for Neuroscience Young Investigator Award, an NIMH MERIT Award, and the 2009 National Alliance for Schizophrenia & Depression Distinguished Investigator Award. He received the 2008 Breakthrough Research Award of the North Carolina Biotechnology Center given to a single scientist in North Carolina, and the 2016 Biomedical Research Award of the Massachusetts Medical Society given to a single business leader in New England. In 2013 he became the 11th recipient of the Thudichum Medal of the Biochemical Society of the United Kingdom. Dr. Ehlers has authored over 100 scientific papers, served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, and Molecular and Cellular Neuroscience, and sat on advisory committees of the National Institutes of Health. He is a member of the McKnight Endowment Fund for Neuroscience Board of Directors, serves on the advisory boards of several private foundations, and advises major pharmaceutical, venture, academic, government, and biotech organizations.